Loading...

Generix

ENXTPA:GENX
Snowflake Description

Reasonable growth potential with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GENX
ENXTPA
€101M
Market Cap
  1. Home
  2. FR
  3. Software
Company description

Generix SA develops SaaS solutions for supply chain ecosystems. The last earnings update was 148 days ago. More info.


Add to Portfolio Compare Print
  • Generix has significant price volatility in the past 3 months.
GENX Share Price and Events
7 Day Returns
1.3%
ENXTPA:GENX
1.6%
FR Software
1%
FR Market
1 Year Returns
45.4%
ENXTPA:GENX
21.7%
FR Software
3.5%
FR Market
GENX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Generix (GENX) 1.3% 12.8% 31.6% 45.4% 64.7% 91.6%
FR Software 1.6% 5.3% 22.1% 21.7% 89.4% 173.4%
FR Market 1% 6% 15% 3.5% 30% 32.9%
1 Year Return vs Industry and Market
  • GENX outperformed the Software industry which returned 21.7% over the past year.
  • GENX outperformed the Market in France which returned 3.5% over the past year.
Price Volatility
GENX
Industry
5yr Volatility vs Market
Related Companies

GENX Value

 Is Generix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Generix to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Generix.

ENXTPA:GENX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:GENX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Software Unlevered Beta Simply Wall St/ S&P Global 1.14
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.137 (1 + (1- 33%) (18.71%))
1.187
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.19
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.187 * 6.65%)
8.63%

Discounted Cash Flow Calculation for ENXTPA:GENX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Generix is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:GENX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.63%)
2019 1.80 Analyst x1 1.66
2020 6.20 Analyst x1 5.25
2021 7.80 Est @ 25.81% 6.09
2022 9.23 Est @ 18.29% 6.63
2023 10.43 Est @ 13.02% 6.89
2024 11.40 Est @ 9.34% 6.94
2025 12.17 Est @ 6.76% 6.82
2026 12.78 Est @ 4.95% 6.59
2027 13.25 Est @ 3.68% 6.29
2028 13.62 Est @ 2.8% 5.95
Present value of next 10 years cash flows €59.11
ENXTPA:GENX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €13.62 × (1 + 0.73%) ÷ (8.63% – 0.73%)
€173.73
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €173.73 ÷ (1 + 8.63%)10
€75.94
ENXTPA:GENX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €59.11 + €75.94
€135.05
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €135.05 / 22.13
€6.1
ENXTPA:GENX Discount to Share Price
Calculation Result
Value per share (EUR) From above. €6.10
Current discount Discount to share price of €4.58
= -1 x (€4.58 - €6.10) / €6.10
25%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Generix is available for.
Intrinsic value
25%
Share price is €4.58 vs Future cash flow value of €6.1
Current Discount Checks
For Generix to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Generix's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Generix's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Generix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Generix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:GENX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in EUR €0.02
ENXTPA:GENX Share Price ** ENXTPA (2019-04-24) in EUR €4.58
France Software Industry PE Ratio Median Figure of 23 Publicly-Listed Software Companies 25.1x
France Market PE Ratio Median Figure of 416 Publicly-Listed Companies 16.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Generix.

ENXTPA:GENX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GENX Share Price ÷ EPS (both in EUR)

= 4.58 ÷ 0.02

203.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Generix is overvalued based on earnings compared to the FR Software industry average.
  • Generix is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does Generix's expected growth come at a high price?
Raw Data
ENXTPA:GENX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 203.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
116.6%per year
France Software Industry PEG Ratio Median Figure of 16 Publicly-Listed Software Companies 2.63x
France Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

ENXTPA:GENX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 203.18x ÷ 116.6%

1.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Generix is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Generix's assets?
Raw Data
ENXTPA:GENX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in EUR €1.61
ENXTPA:GENX Share Price * ENXTPA (2019-04-24) in EUR €4.58
France Software Industry PB Ratio Median Figure of 31 Publicly-Listed Software Companies 1.99x
France Market PB Ratio Median Figure of 617 Publicly-Listed Companies 1.49x
ENXTPA:GENX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GENX Share Price ÷ Book Value per Share (both in EUR)

= 4.58 ÷ 1.61

2.84x

* Primary Listing of Generix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Generix is overvalued based on assets compared to the FR Software industry average.
X
Value checks
We assess Generix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Software industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Software industry average (and greater than 0)? (1 check)
  5. Generix has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GENX Future Performance

 How is Generix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
116.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Generix expected to grow at an attractive rate?
  • Generix's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • Generix's earnings growth is expected to exceed the France market average.
  • Generix's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:GENX Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:GENX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 116.6%
ENXTPA:GENX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 7.7%
France Software Industry Earnings Growth Rate Market Cap Weighted Average 15.6%
France Software Industry Revenue Growth Rate Market Cap Weighted Average 9.1%
France Market Earnings Growth Rate Market Cap Weighted Average 13.4%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:GENX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:GENX Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 112 1
2023-03-31 107 1
2022-03-31 101 1
2021-03-31 94 1
2020-03-31 86 8 5 1
2019-03-31 78 5 2 1
ENXTPA:GENX Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-09-30 73 1 0
2018-06-30 72 2 1
2018-03-31 70 3 1
2017-12-31 69 5 0
2017-09-30 68 6 0
2017-06-30 65 5 0
2017-03-31 63 4 0
2016-12-31 62 2 0
2016-09-30 61 0 1
2016-06-30 60 0 1
2016-03-31 58 0 1
2015-12-31 57 -1 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Generix's earnings are expected to grow significantly at over 20% yearly.
  • Generix's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:GENX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Generix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GENX Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31
2020-03-31 0.22 0.22 0.22 1.00
2019-03-31 0.10 0.10 0.10 1.00
ENXTPA:GENX Past Financials Data
Date (Data in EUR Millions) EPS *
2018-09-30 0.02
2018-06-30 0.03
2018-03-31 0.03
2017-12-31 0.02
2017-09-30 0.01
2017-06-30 0.00
2017-03-31 -0.01
2016-12-31 0.02
2016-09-30 0.04
2016-06-30 0.05
2016-03-31 0.06
2015-12-31 0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Generix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Generix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Generix has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GENX Past Performance

  How has Generix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Generix's growth in the last year to its industry (Software).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Generix's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Generix's 1-year earnings growth exceeds its 5-year average (383.5% vs -49.1%)
  • Generix's earnings growth has exceeded the FR Software industry average in the past year (383.5% vs 17.4%).
Earnings and Revenue History
Generix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Generix Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GENX Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 73.27 0.50 4.69
2018-06-30 71.78 0.53 4.69
2018-03-31 70.29 0.57 4.69
2017-12-31 69.01 0.33 4.38
2017-09-30 67.72 0.10 4.08
2017-06-30 65.36 -0.04 4.08
2017-03-31 63.00 -0.18 4.08
2016-12-31 61.87 0.35 3.76
2016-09-30 60.73 0.87 3.44
2016-06-30 59.56 1.06 3.44
2016-03-31 58.39 1.24 3.44
2015-12-31 57.20 1.92 3.49
2015-09-30 56.01 2.60 3.54
2015-06-30 54.84 2.25 3.54
2015-03-31 53.67 1.91 3.54
2014-12-31 51.92 2.61 3.29
2014-09-30 50.17 3.31 3.05
2014-06-30 49.78 3.75 3.05
2014-03-31 49.40 4.18 3.05
2013-09-30 42.31 1.98 2.93
2013-06-30 45.33 0.92 2.93
2013-03-31 48.34 -0.14 2.93
2012-12-31 63.38 1.13 3.38
2012-09-30 63.62 0.64 3.19
2012-06-30 63.94 -0.74 3.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Generix has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Generix used its assets less efficiently than the FR Software industry average last year based on Return on Assets.
  • Generix's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Generix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Software industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Generix has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GENX Health

 How is Generix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Generix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Generix's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Generix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Generix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Generix Company Filings, last reported 6 months ago.

ENXTPA:GENX Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 39.04 18.97 5.70
2018-06-30 39.04 18.97 5.70
2018-03-31 37.48 13.96 6.78
2017-12-31 37.48 13.96 6.78
2017-09-30 39.80 16.51 5.24
2017-06-30 39.80 16.51 5.24
2017-03-31 39.23 13.16 6.94
2016-12-31 39.23 13.16 6.94
2016-09-30 36.14 18.24 7.34
2016-06-30 36.14 18.24 7.34
2016-03-31 35.98 7.86 5.46
2015-12-31 35.98 7.86 5.46
2015-09-30 35.60 10.36 3.06
2015-06-30 35.60 10.36 3.06
2015-03-31 34.71 7.26 7.99
2014-12-31 34.71 7.26 7.99
2014-09-30 41.08 4.17 9.40
2014-06-30 41.08 4.17 9.40
2014-03-31 42.21 6.13 4.77
2013-09-30 38.98 6.44 2.84
2013-06-30 38.98 6.44 2.84
2013-03-31 38.84 8.67 7.35
2012-12-31 38.84 8.67 7.35
2012-09-30 36.10 12.00 3.25
2012-06-30 36.10 12.00 3.25
  • Generix's level of debt (48.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (16.5% vs 48.6% today).
  • Debt is not well covered by operating cash flow (5.8%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 12.4x coverage).
X
Financial health checks
We assess Generix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Generix has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GENX Dividends

 What is Generix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Generix dividends.
If you bought €2,000 of Generix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Generix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Generix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:GENX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
France Software Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.5%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 2.9%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:GENX Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Generix has not reported any payouts.
  • Unable to verify if Generix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Generix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Generix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Generix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Generix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Generix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GENX Management

 What is the CEO of Generix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aïda Sène
TENURE AS CEO 0.5 years
CEO Bio

Aïda Collette-Sène has been Chief Executive Officer at Generix SA since October 2018.

CEO Compensation
  • Insufficient data for Aïda to compare compensation growth.
  • Insufficient data for Aïda to establish whether their remuneration is reasonable compared to companies of similar size in France.
Management Team

Jean-Charles Deconninck

TITLE
Chairman of Management Board & President
COMPENSATION
€345K
TENURE
0.5 yrs

Ludovic Luzza

TITLE
Chief Financial & Administrative Officer and Member of Management Board
COMPENSATION
€152K

Philippe Seguin

TITLE
Chief Operating Officer
COMPENSATION
€199K

Aïda Sène

TITLE
Chief Executive Officer
TENURE
0.5 yrs

Christophe Verdenne

TITLE
Chief Sales Officer
Board of Directors Tenure

Average tenure of the Generix board of directors in years:

10.5
Average Tenure
  • The average tenure for the Generix board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

François Poirier

TITLE
Chairman of the Supervisory Board
COMPENSATION
€9K
AGE
56
TENURE
7.6 yrs

Gérard Claverie

TITLE
Vice Chairman of Supervisory Board
COMPENSATION
€9K
TENURE
13.4 yrs

Jean-Philippe Gallant

TITLE
Independent Member of the Supervisory Board
COMPENSATION
€9K
AGE
77
TENURE
14.2 yrs

Jean-François Gautier

TITLE
Independent Member of Supervisory Board
COMPENSATION
€9K
TENURE
9.8 yrs

Dominique Despiney

TITLE
Independent Member of the Supervisory Board
COMPENSATION
€9K
TENURE
10.5 yrs

Roland Bonnet

TITLE
Member of Supervisory Board
COMPENSATION
€9K
TENURE
11.4 yrs

Marie-Laure Bordais

TITLE
Member of Supervisory Board
COMPENSATION
€9K
TENURE
7.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Generix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Generix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GENX News

Simply Wall St News

Do Institutions Own Generix SA (EPA:GENX) Shares?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Generix is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Should Generix Be Disappointed With Their 97% Profit?

To wit, the Generix share price has climbed 97% in five years, easily topping the market return of 29% (ignoring dividends). … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During five years of share price growth, Generix actually saw its EPS drop 20% per year.

Simply Wall St -

Should You Be Concerned About Generix SA's (EPA:GENX) ROE?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Generix has a return on equity of 2.8% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Investors Should Know About Generix SA's (EPA:GENX) Financial Strength

Investors are always looking for growth in small-cap stocks like Generix SA (EPA:GENX), with a market cap of €71m. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is

Simply Wall St -

What Percentage Of Generix SA (EPA:GENX) Shares Do Insiders Own?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

What Should Investors Know About Generix SA's (EPA:GENX) Return On Capital?

This share represents a portion of capital used by the company to operate the business, and it is important the company is able to use the capital base efficiently to create adequate cash flows for you as an investor. … Thus, to understand how your money can grow by investing in Generix, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE) … Calculating Return On Capital Employed for GENX

Simply Wall St -

A Closer Look At Generix SA's (EPA:GENX) Uninspiring ROE

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every €1 worth of equity in the company, it was able to earn €0.032. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Who Owns Generix SA (EPA:GENX)?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of €79.7m, Generix is a small cap stock, so it might not be well known by many institutional investors. … Let's take a closer look to see what the different types of shareholder can tell us about GENX

Simply Wall St -

Should You Be Happy With Generix SA's (EPA:GENX) Performance Lately?

Examining Generix SA's (EPA:GENX) past track record of performance is an insightful exercise for investors. … Today I will assess GENX's latest performance announced on 31 March 2018 and compare these figures to its longer term trend and industry movements. … How Did GENX's Recent Performance Stack Up Against Its Past

Simply Wall St -

Is It Time To Buy Generix SA (EPA:GENX)?

As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Is there still an opportunity here to buy. … Today I will analyse the most recent data on Generix’s outlook and valuation to see if the opportunity still exists

Simply Wall St -

GENX Company Info

Description

Generix SA develops SaaS solutions for supply chain ecosystems. The company's supply chain hub platform offers supply chain execution solutions, including warehouse management software; transport management software to reduce transport costs and associated administrative charges; manufacturing execution system that connects the warehouse to the production floor; enterprise asset management solution for inventory visibility in the field, spare parts management, and asset visibility and tracking; yard management software; and logistics order management system. Its supply chain hub platform also provides B2B integration solutions, such as EDI software, invoice services solution, finance and government services solution, and fax/PDF/OCR solution; and collaboration and visibility solutions comprising supplier, customer, carrier, 3PL, and invoice portals, as well as stock replenishment software, and order tracking and supply chain finance solutions. In addition, the company’s supply chain hub platform offers collaborative network; onboarding services, a solution that enables businesses to automate the process of enlisting B2B counterparts; and data lake, a key to analytics and predictive analytics. Further, it provides TradeXpress, a B2B integration software that supports various inter-application modes of mediation, such as EDI, B2B, MFT, ETL, EAI, and ESB, as well as management of regulated flows; and solutions for customer loyalty and interaction. The company operates in 50 countries worldwide. It primarily serves manufacturers, third-party logistics providers (3PL), and retailers. Generix SA was founded in 1990 and is headquartered in Lesquin, France.

Details
Name: Generix SA
GENX
Exchange: ENXTPA
Founded: 1990
€101,343,258
22,127,349
Website: http://www.generixgroup.com
Address: Generix SA
ARTEPARC - Bât. A,
2 rue des Peupliers,
Lesquin,
Nord-Pas-de-Calais, 59810,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GENX Ordinary Shares Euronext Paris FR EUR 16. Jul 1998
LSE 0JAW Ordinary Shares London Stock Exchange GB EUR 16. Jul 1998
BATS-CHIXE GENXP Ordinary Shares BATS 'Chi-X Europe' GB EUR 16. Jul 1998
Number of employees
Current staff
Staff numbers
527
Generix employees.
Industry
Application Software
Software
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:27
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/14
Last earnings filing: 2018/11/27
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.